{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:03:24Z","timestamp":1784937804978,"version":"3.55.0"},"reference-count":24,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"unspecified","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Research and Development Fund of Region Kronoberg","award":["936015"],"award-info":[{"award-number":["936015"]}]},{"name":"Research and Development Fund of Region Kronoberg","award":["969355"],"award-info":[{"award-number":["969355"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2024,6,17]]},"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>To explore whether circulating matrix metalloproteinase-2 (MMP-2), MMP-9, MMP-9\/neutrophil gelatinase-associated lipocalin, MMP-9\/tissue inhibitor of metalloproteinase-1 (TIMP-1), MMP-14, TIMP-2 and TIMP-3 were associated with the severity and progression of diabetic retinopathy (DR) in patients with type 1 diabetes (T1D).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Baseline and prospective analyses were conducted over a period of 10.5 person-years. In 2009, recruitment and biochemical analyses (MMPs, TIMPs, glycated haemoglobin (HbA1c), serum creatinine, macroalbuminuria) were performed. Fundus photography, performed at baseline and at follow-up in accordance with the regional screening programme, was compared after being categorised according to the International Clinical Diabetic Retinopathy Disease Severity Scale. \u2018DR progression at least one leve\u2019 was calculated. High MMP-2 was defined as \u2265178\u2009ng\/mL (\u226575th percentile) and high TIMP-2 as \u2265205\u2009ng\/mL (\u226575th percentile). DR was dichotomised as \u2018at least moderate DR\u2019 or \u2018no\/mild DR\u2019.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The study included 267 participants, 57% of whom were men. At baseline, the prevalence of high MMP-2 (p=0.001) and high TIMP-2 (p=0.008) increased with the severity of DR. \u2018At least moderate DR\u2019 (adjusted OR (AOR) 2.4, p=0.008) and macroalbuminuria (AOR 3.6, p=0.025) were independently associated with high MMP-2. \u2018At least moderate DR\u2019 (AOR 2.3, p=0.009) and macroalbuminuria (3.4, p=0.031) were independently associated with high TIMP-2. DR progression occurred in 101 (46%) patients (p&lt;0.001). HbA1c\u226553\u2009mmol\/mol was associated with the progression of DR (crude OR 3.8, p=0.001). No other MMPs or TIMPs were linked to the severity or the progression of DR.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>High levels of MMP-2 and TIMP-2 indicated more severe DR or diabetic nephropathy. Only HbA1c was associated with the progression of DR in 267 patients with T1D.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjophth-2023-001583","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T19:35:35Z","timestamp":1720726535000},"page":"e001583","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Plasma matrix metalloproteinases and tissue inhibitors of metalloproteinases explored in relation to the severity and progression of diabetic retinopathy in patients with type 1 diabetes: baseline and prospective analyses"],"prefix":"10.1136","volume":"9","author":[{"given":"Sven","family":"Hector","sequence":"first","affiliation":[{"name":"Clinical Sciences, Ophthalmology, Lund University Faculty of Medicine, Lund, Sweden"},{"name":"Department of Ophthalmology, Central Hospital, Region Kronoberg Healthcare providers, V\u00e4xj\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Olav","family":"Thulesius","sequence":"additional","affiliation":[{"name":"Department of Medicine and Optometry, Linnaeus University, Kalmar, Sweden"},{"name":"Clinical Sciences, Division of Family Medicine, Lund University, Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Thunander","sequence":"additional","affiliation":[{"name":"Clinical Sciences, Diabetology and Endocrinology, Lund University, Faculty of Medicine, Lund, Sweden"},{"name":"Diabetes Research Laboratory, Biomedical Centre, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Hillman","sequence":"additional","affiliation":[{"name":"Diabetes Research Laboratory, Biomedical Centre, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Landin-Olsson","sequence":"additional","affiliation":[{"name":"Clinical Sciences, Diabetology and Endocrinology, Lund University, Faculty of Medicine, Lund, Sweden"},{"name":"Diabetes Research Laboratory, Biomedical Centre, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7835-2650","authenticated-orcid":false,"given":"Eva Olga","family":"Melin","sequence":"additional","affiliation":[{"name":"Clinical Sciences, Diabetology and Endocrinology, Lund University, Faculty of Medicine, Lund, Sweden"},{"name":"Diabetes Research Laboratory, Biomedical Centre, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"key":"2025090109104911000_9.1.e001583.1","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.18240\/ijo.2022.07.20","article-title":"Molecules related to diabetic retinopathy in the vitreous and involved pathways","volume":"15","author":"Xia","year":"2022","journal-title":"Int J Ophthalmol"},{"key":"2025090109104911000_9.1.e001583.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2014.03.003"},{"key":"2025090109104911000_9.1.e001583.3","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.2337\/dc22-0239","article-title":"Impact of Hba1C followed 32 years from diagnosis of type 1 diabetes on development of severe retinopathy and nephropathy: the VISS study","volume":"45","author":"Arnqvist","year":"2022","journal-title":"Diabetes Care"},{"key":"2025090109104911000_9.1.e001583.4","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4894","article-title":"HbA1c level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population based cohort study","volume":"366","author":"Lind","year":"2019","journal-title":"BMJ"},{"key":"2025090109104911000_9.1.e001583.5","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2023-001314","article-title":"Soluble Cd163 and glycated haemoglobin were independently associated with the progression of diabetic retinopathy in adult patients with type 1 diabetes","volume":"8","author":"Hector","year":"2023","journal-title":"BMJ Open Ophthalmol"},{"key":"2025090109104911000_9.1.e001583.6","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.84.10.1091"},{"key":"2025090109104911000_9.1.e001583.7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.lfs.2019.05.038","article-title":"MMP targeting in the battle for vision: recent developments and future prospects in the treatment of diabetic retinopathy","volume":"229","author":"Drankowska","year":"2019","journal-title":"Life Sci"},{"key":"2025090109104911000_9.1.e001583.8","first-page":"1308","article-title":"Metalloproteinases as mediators of inflammation and the eyes: molecular genetic underpinnings governing ocular pathophysiology","volume":"10","author":"Singh","year":"2017","journal-title":"Int J Ophthalmol"},{"key":"2025090109104911000_9.1.e001583.9","first-page":"394","article-title":"Matrix metalloproteinase-14 is a biomarker of angiogenic activity in proliferative diabetic retinopathy","volume":"24","author":"Abu El-Asrar","year":"2018","journal-title":"Mol Vis"},{"key":"2025090109104911000_9.1.e001583.10","doi-asserted-by":"publisher","DOI":"10.2337\/db13-0014"},{"key":"2025090109104911000_9.1.e001583.11","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1166\/mex.2021.1982","article-title":"Basic regulatory effects and clinical value of metalloproteinase-14 and extracellular matrix metalloproteinase inducer in diabetic retinopathy","volume":"11","author":"Li","year":"2021","journal-title":"Mat Express"},{"key":"2025090109104911000_9.1.e001583.12","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-015-0195-2"},{"key":"2025090109104911000_9.1.e001583.13","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-0162"},{"key":"2025090109104911000_9.1.e001583.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2005.11.029"},{"key":"2025090109104911000_9.1.e001583.15","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-010-9308-6"},{"key":"2025090109104911000_9.1.e001583.16","doi-asserted-by":"publisher","DOI":"10.1515\/BC.2007.123"},{"key":"2025090109104911000_9.1.e001583.17","first-page":"2432","article-title":"Tissue inhibitor of metalloproteinase-3 ameliorates diabetes-induced retinal inflammation","volume":"12","author":"Abu El-Asrar","year":"2021","journal-title":"Front Physiol"},{"key":"2025090109104911000_9.1.e001583.18","doi-asserted-by":"crossref","unstructured":"Melin EO , Dereke J , Hillman M . Galectin-3, metalloproteinase-2 and cardiovascular disease were independently associated with metalloproteinase-14 in patients with type 1 diabetes: a cross sectional study. Diabetol Metab Syndr 2021;13. doi:10.1186\/s13098-021-00727-3","DOI":"10.1186\/s13098-021-00727-3"},{"key":"2025090109104911000_9.1.e001583.19","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-0137"},{"key":"2025090109104911000_9.1.e001583.20","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1530\/EC-18-0336","article-title":"Soluble CD163 was linked to galectin-3, diabetic retinopathy and antidepressants in type 1 diabetes","volume":"7","author":"Melin","year":"2018","journal-title":"Endocr Connect"},{"key":"2025090109104911000_9.1.e001583.21","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/aos.13936","article-title":"Evidence\u2010based Danish guidelines for screening of diabetic retinopathy","volume":"96","author":"Grauslund","year":"2018","journal-title":"Acta Ophthalmologica"},{"key":"2025090109104911000_9.1.e001583.22","doi-asserted-by":"crossref","first-page":"728089","DOI":"10.3389\/fmed.2021.728089","article-title":"Effects of Sglt2 inhibitors on renal outcomes in patients with chronic kidney disease: a meta-analysis","volume":"8","author":"Li","year":"2021","journal-title":"Front Med"},{"key":"2025090109104911000_9.1.e001583.23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/17446651.2022.2078305","article-title":"Improving the screening of risk factors in diabetic retinopathy","volume":"17","author":"Scanlon","year":"2022","journal-title":"Expert Rev Endocrinol Metab"},{"key":"2025090109104911000_9.1.e001583.24","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.2337\/dc22-0926","article-title":"Range of risk factor levels, risk control, and temporal trends for nephropathy and end-stage kidney disease in patients with type 1 and type 2 diabetes","volume":"45","author":"Halminen","year":"2022","journal-title":"Diabetes Care"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2023-001583","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T16:11:13Z","timestamp":1756743073000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2023-001583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,7,11]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1136\/bmjophth-2023-001583"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2023-001583","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}